FindTrial
Sign In

The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02251847
Enrollment
400
Registered
2014-09-29
Start date
2014-07-31
Completion date
Unknown
Last updated
2014-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Keywords

cholesterol

Brief summary

To evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients

Detailed description

To evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients

Interventions

DRUGRosuvastatin/Ezetimibe

Rosuvastatin 5mg

Sponsors

IlDong Pharmaceutical Co Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Hypercholesterolemic patient

Exclusion criteria

* Has history of hypersensitivity to HMG-CoA reductase inhibitor and Ezetimibe

Design outcomes

Primary

MeasureTime frame
Percent change from baseline to 8 week in LDL-Cholesterolbaseline and 8 week

Secondary

MeasureTime frame
Percent change from baseline to 4 week in LDL-Cholesterolbaseline and 4 week

Countries

South Korea

Contacts

Primary ContactMin-Hee Kwon
minhee@ildong.com02-526-3379

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026